idelalisib + rituximab + ifosfamide + carboplatin + etoposide

This regimen is a **combination therapy** that includes five distinct antineoplastic agents: - **Idelalisib**: A small molecule inhibitor targeting phosphatidylinositol 3-kinase delta (PI3Kδ). It induces apoptosis and inhibits proliferation of malignant B-cells, commonly used in certain lymphoid malignancies. - **Rituximab**: A chimeric monoclonal antibody targeting CD20 on B lymphocytes, leading to B-cell depletion[1][3][5]. It is widely used in non-Hodgkin lymphoma, chronic lymphocytic leukemia, and various autoimmune disorders. - **Ifosfamide**: An alkylating agent of the oxazaphosphorine class that inhibits DNA replication and function by forming DNA cross-links. - **Carboplatin**: A platinum compound that causes DNA damage through the formation of intrastrand and interstrand crosslinks, impeding DNA synthesis and function. - **Etoposide**: A podophyllotoxin derivative that inhibits topoisomerase II, thereby causing DNA strand breaks and apoptosis. This multi-agent regimen is investigational as a combination and has only partial preclinical and clinical precedent; combinations such as ICE (ifosfamide, carboplatin, and etoposide) are established for lymphoma and certain solid tumors[2][4][6][8]. Rituximab is routinely added to regimens for B-cell malignancies, while idelalisib is approved for certain refractory lymphoid malignancies. The full five-drug combination is not a standard named protocol.